Literature DB >> 10146877

Economic aspects of pharmacokinetic services.

C J Destache.   

Abstract

Mesh：

Year:  1993        PMID： 10146877     DOI： 10.2165/00019053-199303060-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  15 in total

1.  Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring.

Authors:  J S Bertino; L A Booker; P A Franck; P L Jenkins; K R Franck; A N Nafziger
Journal:  J Infect Dis       Date:  1993-01       Impact factor: 5.226

2.  Individualizing gentamicin dosage regimens in burn patients with gram-negative septicemia: a cost--benefit analysis.

Authors:  J L Bootman; A I Wertheimer; D Zaske; C Rowland
Journal:  J Pharm Sci       Date:  1979-03       Impact factor: 3.534

3.  Does accepting pharmacokinetic recommendations impact hospitalization? A cost-benefit analysis.

Authors:  C J Destache; S K Meyer; K M Rowley
Journal:  Ther Drug Monit       Date:  1990-09       Impact factor: 3.681

4.  Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: a cost-benefit analysis.

Authors:  C J Destache; S K Meyer; M J Bittner; K G Hermann
Journal:  Ther Drug Monit       Date:  1990-09       Impact factor: 3.681

5.  What is the cost of nephrotoxicity associated with aminoglycosides?

Authors:  J M Eisenberg; H Koffer; H A Glick; M L Connell; L E Loss; G H Talbot; N H Shusterman; B L Strom
Journal:  Ann Intern Med       Date:  1987-12       Impact factor: 25.391

6.  Positive impact of a therapeutic drug-monitoring program on total aminoglycoside dose and cost of hospitalization.

Authors:  K D Crist; M C Nahata; J Ety
Journal:  Ther Drug Monit       Date:  1987-09       Impact factor: 3.681

7.  Cost analysis of an aminoglycoside pharmacokinetic dosing program.

Authors:  J H Schloemer; J J Zagozen
Journal:  Am J Hosp Pharm       Date:  1984-11

8.  A controlled trial of the cost benefit of computerized bayesian aminoglycoside administration.

Authors:  M E Burton; C L Ash; D P Hill; T Handy; M D Shepherd; M R Vasko
Journal:  Clin Pharmacol Ther       Date:  1991-06       Impact factor: 6.875

9.  Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides for gram-negative infections.

Authors:  C J Destache; S K Meyer; M T Padomek; B G Ortmeier
Journal:  DICP       Date:  1989-01

10.  Outcome of patients treated by an aminoglycoside pharmacokinetic dosing service.

Authors:  K J Sveska; B D Roffe; D K Solomon; R P Hoffmann
Journal:  Am J Hosp Pharm       Date:  1985-11
View more
  2 in total

Review 1.  Therapeutic drug monitoring: do the improved outcomes justify the costs?

Authors:  G E Schumacher; J T Barr
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 2.  The economic potential of dual individualisation methodologies.

Authors:  J A Paladino; G S Zimmer; J J Schentag
Journal:  Pharmacoeconomics       Date:  1996-12       Impact factor: 4.981
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.